Oxford Asset Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Oxford Asset Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-25,660	Closed	-$22K	–	2084
2019 Q2	$22K	Sell	25,660 -11,658	-31%	-$18.2K	﹤0.01%	1653
2019 Q1	$87K	Sell	37,318 -2,559	-6%	-$6.93K	﹤0.01%	1578
2018 Q4	$93K	Buy	+39,877	New	+$352K	﹤0.01%	1656

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Oxford Asset Management's SNNA Position: Q3 2019 in Review

Oxford Asset Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 25,660 shares — an estimated $22K sold.

Oxford Asset Management first reported a position in SNNA in Q4 2018 and held it in 3 quarters. The position peaked at $93K in Q4 2018. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

Oxford Asset Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Oxford Asset Management sold 25,660 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $22K.
Oxford Asset Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2018 and held it in 3 quarters.
Oxford Asset Management's Sienna Biopharmaceuticals, Inc. position peaked at $93K in Q4 2018.
23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Oxford Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.